Arsenic Trioxide and Icariin Show Synergistic Anti-leukemic Activity

详细信息    查看全文

• 作者：Zhi Wang ; Hong Zhang ; Liling Dai ; Tongguo Song ; Ping Li…
• 关键词：APL ; Icariin ; ATO ; ROS ; Synergistic effect
• 刊名：Cell Biochemistry and Biophysics
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：73
• 期：1
• 页码：213-219
• 全文大小：1,707 KB
• 参考文献：1.Estey, E., & Dohner, H. (2006). Acute myeloid leukaemia. Lancet, 368(9550), 1894鈥?907.View Article PubMed
  2.Rogers, C. S., et al. (2014). Vitamin D3 potentiates the antitumorigenic effects of arsenic trioxide in human leukemia (HL-60) cells. Experimental Hematology and Oncology, 3(1), 9.PubMed Central View Article PubMed
  3.Borrow, J., et al. (1990). Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science, 249(4976), 1577鈥?580.View Article PubMed
  4.de The, H., et al. (1990). The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature, 347(6293), 558鈥?61.View Article PubMed
  5.Cyranoski, D. (2007). Arsenic patent keeps drug for rare cancer out of reach of many. Nature Medicine, 13(9), 1005.View Article PubMed
  6.Shen, Z. X., et al. (1997). Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 89(9), 3354鈥?360.PubMed
  7.Soignet, S. L., et al. (1998). Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New England Journal of Medicine, 339(19), 1341鈥?348.View Article PubMed
  8.Fox, E., et al. (2008). Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood, 111(2), 566鈥?73.PubMed Central View Article PubMed
  9.Ebinger, M., et al. (2011). Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy. Pediatric Hematology and Oncology, 28(4), 334鈥?37.View Article PubMed
  10.Douer, D., & Tallman, M. S. (2005). Arsenic trioxide: New clinical experience with an old medication in hematologic malignancies. Journal of Clinical Oncology, 23(10), 2396鈥?410.View Article PubMed
  11.Sanz, M. A., et al. (2009). Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 113(9), 1875鈥?891.View Article PubMed
  12.Li, S., et al. (2010). Icariin, a natural flavonol glycoside, induces apoptosis in human hepatoma SMMC-7721 cells via a ROS/JNK-dependent mitochondrial pathway. Cancer Letters, 298(2), 222鈥?30.View Article PubMed
  13.Lin, C. C., et al. (2004). Cytotoxic effects of Coptis chinensis and Epimedium sagittatum extracts and their major constituents (berberine, coptisine and icariin) on hepatoma and leukaemia cell growth. Clinical and Experimental Pharmacology and Physiology, 31(1鈥?), 65鈥?9.View Article PubMed
  14.Wang, Y., et al. (2010). Icariin exterts negative effects on human gastric cancer cell invasion and migration by vasodilator-stimulated phosphoprotein via Rac1 pathway. European Journal of Pharmacology, 635(1鈥?), 40鈥?8.View Article PubMed
  15.Zhang, D. C., et al. (2013). Icariin potentiates the antitumor activity of gemcitabine in gallbladder cancer by suppressing NF-魏B. Acta Pharmacologica Sinica, 34(2), 301鈥?08.PubMed Central View Article PubMed
  16.Yang, L., et al. (2014). Synergistic anti-cancer effects of Icariin and temozolomide in glioblastoma. Cell Biochemistry and Biophysics. 2014. doi:10.鈥?007/鈥媠12013-014-0360-3 .
  17.Shi, D. B., et al. (2014). Icariin-mediated inhibition of NF-魏B activity enhances the in vitro and in vivo antitumour effect of 5-fluorouracil in colorectal cancer. Cell Biochemistry and Biophysics, 69(3), 523鈥?30.View Article PubMed
  18.Li, W., et al. (2014). Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma. Cell Biochemistry and Biophysics, 68(2), 427鈥?36.View Article PubMed
  19.Chou, T. C., & Talalay, P. (1984). Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 27鈥?5.View Article PubMed
  20.Wang, D., et al. (2008). Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs. International Journal of Urology, 15(5), 435鈥?41.View Article PubMed
  21.Liou, G. Y., & Storz, P. (2010). Reactive oxygen species in cancer. Free Radical Research, 44(5), 479鈥?96.View Article PubMed
  22.Chen, Y., et al. (2011). Icariin and its pharmaceutical efficacy: Research progress of molecular mechanism. Zhong Xi Yi Jie He Xue Bao, 9(11), 1179鈥?184.View Article PubMed
  23.Huang, X., Zhu, D., & Lou, Y. (2007). A novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells. European Journal of Pharmacology, 564(1鈥?), 26鈥?6.View Article PubMed
  24.Wang, Y., et al. (2010). Icariin exterts negative effects on human gastric cancer cell invasion and migration by vasodilator-stimulated phosphoprotein via Rac1 pathway. European Journal of Pharmacology, 635(1鈥?), 40鈥?8.View Article PubMed
  25.Wang, Q., et al. (2011). Icariin induces apoptosis in mouse MLTC-10 Leydig tumor cells through activation of the mitochondrial pathway and down-regulation of the expression of piwil4. International Journal of Oncology, 39(4), 973鈥?80.PubMed
  26.Tatham, M. H., et al. (2008). RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nature Cell Biology, 10(5), 538鈥?46.View Article PubMed
  27.Chen, G. Q., et al. (1997). Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood, 89(9), 3345鈥?353.PubMed
  28.Yang, C. H., et al. (1999). Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. British Journal of Cancer, 81(5), 796鈥?99.PubMed Central View Article PubMed
  29.Chou, W. C., et al. (2004). Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proceedings of the National Academy of Sciences of the United States of America, 101(13), 4578鈥?583.PubMed Central View Article PubMed
  30.Fan, Y., et al. (2014). Arsenic trioxide and resveratrol show synergistic anti-leukemia activity and neutralized cardiotoxicity. PLoS ONE, 9(8), e105890.PubMed Central View Article PubMed
  31.Benbijja, M., Mellouk, A., & Bobe, P. (2014). Sensitivity of leukemic T-cell lines to arsenic trioxide cytotoxicity is dependent on the induction of phosphatase B220/CD45R expression at the cell surface. Molecular Cancer, 13, 251.PubMed Central View Article PubMed
  32.Wo, Y. B., et al. (2008). Reactive oxygen species involved in prenylflavonoids, icariin and icaritin, initiating cardiac differentiation of mouse embryonic stem cells. Journal of Cellular Biochemistry, 103(5), 1536鈥?550.View Article PubMed
  33.Ding, L., et al. (2008). Involvement of p38MAPK and reactive oxygen species in icariin-induced cardiomyocyte differentiation of murine embryonic stem cells in vitro. Stem Cells and Development, 17(4), 751鈥?60.View Article PubMed
  34.Zeng, K. W., et al. (2010). Icariin attenuates lipopolysaccharide-induced microglial activation and resultant death of neurons by inhibiting TAK1/IKK/NF-魏B and JNK/p38 MAPK pathways. International Immunopharmacology, 10(6), 668鈥?78.View Article PubMed
  35.Xiao-Hong, D., et al. (2013). Icariin delays homocysteine-induced endothelial cellular senescence involving activation of the PI3K/AKT-eNOS signaling pathway. Pharmaceutical Biology, 51(4), 433鈥?40.View Article PubMed
  36.Zhou, H., et al. (2014). Icariin attenuates angiotensin II-induced hypertrophy and apoptosis in H9c2 cardiomyocytes by inhibiting reactive oxygen species-dependent JNK and p38 pathways. Experimental and Therapeutic Medicine, 7(5), 1116鈥?122.PubMed Central PubMed
  
• 作者单位：Zhi Wang (1)
  Hong Zhang (1)
  Liling Dai (1)
  Tongguo Song (2)
  Ping Li (1)
  Yali Liu (1)
  Luning Wang (1)
  
  1. Department of Pharmacy, The Affiliated Hospital of Medical College Qingdao University, Qingdao, 266003, China
  2. Emergency Department of Qingdao Emergency Center, Qingdao, 266035, China
  
• 刊物主题：Biochemistry, general; Pharmacology/Toxicology; Biotechnology; Cell Biology; Biophysics and Biological Physics;
• 出版者：Springer US
• ISSN：1559-0283

文摘

Although As2O3 (ATO) has been recommended as the front-line agent for treatment of acute promyelocytic leukemia (APL), particularly for relapsed or refractory APL, it has been associated with profound toxicity. Icariin is a natural compound with activity against a variety of cancers. This study was designed to investigate the effect of Icariin on APL cells and to determine whether Icariin can potentiate the antitumor activity of ATO in APL cells. Cell proliferation and apoptosis were measured using MTT assay and flow cytometry, respectively. The expression of apoptosis and proliferation-related molecules was detected by Western blotting. Reactive oxygen species (ROS) and mitochondrial membrane potential were determined with florescence staining. Icariin inhibited proliferation in a dose-dependent manner and induced apoptosis in both of the tested APL cell lines. Icariin enhanced the in vitro antitumor activity of ATO against APL. The antitumor activity of Icariin and its enhancement of the antitumor activity of ATO correlated with the increase in accumulation of intracellular ROS. Our results showed that Icariin, by increasing intracellular ROS, exhibited antitumor activity and potentiated the antitumor activity of ATO against APL. Therefore, combination treatment with Icariin and ATO might offer a novel therapeutic option for patients with APL, although further studies are needed.